Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Head and neck cancer Stories

2011-11-07 13:27:00

SILVER SPRING, Md., Nov. 7, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Combined with chemotherapy, Erbitux extended the lives of those receiving the treatment combination compared with those receiving chemotherapy alone. Erbitux already is FDA-approved for certain types of...

2011-11-05 01:21:46

The combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma (NPC), according to a phase III study published Nov. 4 in the Journal of the National Cancer Institute. Nasopharyngeal carcinoma is endemic in Southern China and Southeast Asia, where radiotherapy (RT) has been the primary treatment. Although the National Comprehensive Cancer Network (NCCN) recommends concurrent chemo-radiotherapy (CCRT) for...

2011-10-11 09:20:13

Oral Squamous Cell Carcinoma (OSCC) is responsible for nearly a quarter of all head and neck cancers. It is one of the leading causes of cancer death - largely due to the failure of current histological procedures in predicting the recurrence of the disease. New research published in BioMed Central's open access journal BMC Cancer shows that a four-gene signature may accurately predict which patients are at higher risk of OSCC recurrence. A team of researchers, including Drs. Patricia Reis...

2011-10-05 08:15:00

SAN DIEGO, Oct. 5, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier® and HER2osome(TM) cancer therapy will be the subject of a presentation at the Exosomes and Microvesicles 2011 conference on October 17th. The event is being held at the Wyndham Lake Buena Vista Resort located in Walt Disney World, Florida. Dr. Annette...

2011-10-04 12:02:19

Researchers from Boston Medical Center (BMC) and Boston University School of Medicine (BUSM) have found that among advanced head and neck cancer (HNC) patients receiving radiation-based treatment (RT), being non-English speaking (NES) was a more significant predictor of treatment outcome than being of non-white race. The findings, to be presented at the 53rd annual American Society for Radiation Oncology (ASTRO) annual meeting in Miami, Florida, suggest that language barriers may play a role...

2011-10-04 11:52:13

Patients who have high-risk non-melanoma skin carcinomas of the head and neck may benefit from concomitant radiotherapy and chemotherapy, according to a UNC-led study. Their study is the first to report on multiple patients with these skin carcinomas treated simultaneously with radio-and chemotherapy. Scientists with the UNC Lineberger Comprehensive Cancer Center reported their findings in the Sept. 26, 2011 online issue of the International Journal of Surgery. Non-melanoma skin...

2011-10-03 19:39:58

Researchers have determined that a combination of P16 immunohistochemistry and DNA qPCR to test for viral E6 can accurately determine the oropharyngeal squamous cell carcinoma, a form of head and neck cancer, which derive from HPV16, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. "This has immediate clinical applications as we consider recruitment to clinical trials designed to de-escalate the intensity of therapy...

2011-09-26 13:46:00

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology(TM) therapies to treat solid tumor cancers, announced today clinical study results presented at the Fire, Ice and Beyond: The Future of Ablation Therapies conference in Las Vegas, NV, September 23-24. OncoSec's exhibition highlighted a poster titled, "OMS ElectroChemotherapy: Targeted Ablation of Solid Tumors using Reversible Electroporation in...

2011-09-26 11:06:41

Study hopes to standardize clinical practice across Europe First results from an international comparison of the care of patients with rectal cancer have shown there are substantial differences in the use of chemotherapy and radiotherapy between European countries. The European Registration of Cancer Care (EURECCA) study, initiated by ECCO — the European CanCer Organisation — compared the treatment of 6,597 patients in Sweden, Norway, Denmark and The Netherlands who were...

2011-09-26 05:01:00

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology(TM) therapies to treat solid tumor cancers, announced today clinical study results presented at the Fire, Ice and Beyond: The Future of Ablation Therapies conference in Las Vegas, NV, September 23-24. OncoSec's exhibition highlighted a poster titled, "OMS ElectroChemotherapy: Targeted Ablation of Solid Tumors using Reversible Electroporation in...